肿瘤免疫靶点 | CD33 - 知乎 - 知乎专栏
Gemtuzumab ozogamicin （GO，辉瑞，CD33单抗+N-乙酰-卡奇霉素）是目前唯一获批上市靶向CD33的抗体药物。 （数据来源Walter RB, et al. Blood. 2012） GO曾在2000年就获得FDA批 …
Gemtuzumab ozogamicin for acute myeloid leukemia
2017年11月30日 · On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin (GO) for the treatment of adults with newly diagnosed CD33 + acute …
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid …
Gemtuzumab ozogamicin (GO), a humanized murine IgG4 anti-CD33 antibody, is the first target therapy approved in AML therapeutic scenario. This review focuses on current biological …
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33 …
In September 2017, the US FDA announced re-approval of gemtuzumab ozogamicin (GO), a CD33-targeting immunoconjugate, for treatment of newly diagnosed and relapsed/refractory …
CD33 Expression and Its Association With Gemtuzumab …
CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, …
Gemtuzumab ozogamicin in acute myeloid leukemia | Leukemia
2017年6月13日 · Efforts to target CD33 therapeutically have focused on gemtuzumab ozogamicin (GO; Mylotarg), an antibody-drug conjugate delivering a DNA-damaging calicheamicin …
Gemtuzumab ozogamicin and novel antibody-drug conjugates in …
2019年10月31日 · Single-agent GO is effective and safe for AML patient ineligible for intensive chemotherapy. Multiple combination regimens incorporating GO have also been …
吉妥珠单抗在CD33阳性急性髓系白血病中的研究进展
吉妥珠单抗（gemtuzumab ozogamicin，GO）是一种由人源化抗CD33单抗与脱氧核糖核酸（deoxyribonucleic acid，DNA）嵌入剂卡奇霉素（calicheamicin，CLM）形成的抗体偶联药物 …
柏思荟研究报告 | 靶向CD33药物在研现 - 雪球
2022年2月16日 · Mylotarg（Gemtuzumab Ozoganmicin，GO）是由抗CD33 IgG4单抗偶联卡奇霉素而成的ADC药物，由辉瑞公司研发，为全球首款上市的ADC药物。Mylotarg与AML细胞膜表 …
靶CD33 ADC | Gemtuzumab ozogamicin 奥加吉妥珠单抗 - 知乎
CD33抗原分子表达于髓系细胞，特别高表达于急性髓系白血病（AML）细胞面表（85%~90%），且低表达于正常造血细胞，因此极具AML靶向治疗价值。 急性髓系白血病正 …